US3755581036
© BusinessWire
09.12.2025
GILD
LISTED
NASDAQ
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
News Preview
Gilead Foundation today announced a commitment of more than $3 million in new grants to help address critical gaps in education, care delivery and support services for people affected by metastatic breast cancer (mBC). Building on more than $21 million in support since 2021, funding distributed through the Gilead Foundation advances efforts to imp...
Themefolio
Profiler
Peergroup
© BusinessWire
07.12.2025
GILD
LISTED
NASDAQ
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
News Preview
Kite, a Gilead Company (Nasdaq: GILD), presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), even among those ineligible for the previous standard of care, high-dose chemotherapy followed by an autol...
Themefolio
Profiler
Peergroup
© BusinessWire
06.12.2025
GILD
LISTED
NASDAQ
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
News Preview
Kite, a Gilead Company (Nasdaq: GILD), and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which continues to show clinically meaningful deep and durable efficacy with predictable and manageable safety observed to date in relapsed o...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
06.12.2025
GILD
LISTED
NASDAQ
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
News Preview
Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The results of the analysis were shared in an oral presentation (A...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
24.11.2025
GILD
LISTED
NASDAQ
Gilead Foundation Commits Over $3 Million to Address Food Insecurity
News Preview
Gilead Foundation today announced that it has committed over $3 million in grants to expand access to food in communities across the United States. Gilead Foundation Healing Hunger awards will enable 14 regionally focused organizations to meet the unique needs of their communities by improving long-term nutrition access. The funding, distributed t...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2025
GILD
LISTED
NASDAQ
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure prophylaxis (PrEP) to Eswatini and Zambia. The deliveries advance ongoing efforts to accelerate equitable access to long-acting HIV prevention opti...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
GILD
LISTED
NASDAQ
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
News Preview
Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
GILD
LISTED
NASDAQ
Gilead Provides Update on Phase 3 ASCENT-07 Study
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer patients did not meet the primary endpoint of progression-free survival (PFS) as assessed by Blinded...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
GILD
LISTED
NASDAQ
Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new long-term data reinforcing the safety and efficacy profile of Livdelzi® (seladelpar) for people living with primary biliary cholangitis (PBC). Findings support Livdelzi's consistent efficacy and safety outcomes in patients switching from obeticholic acid and positive impact on liver stiffnes...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
GILD
LISTED
NASDAQ
Gilead Sciences to Present at Upcoming Investor Conferences
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
UBS Global Healthcare Conference on Monday, November 10 at 11:00 AM Eastern Time
Jefferies Global Healthcare Conference in London on Wednesday, November 19 at 2:00 PM Greenwich Mean Time
Citi’s Global Healthcare...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
GILD
LISTED
NASDAQ
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, during the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (December 6-9). These data showcase Kite’s continued progress in transforming blood cancer care and expanding the reach and impact of CAR T-ce...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2025
GILD
LISTED
NASDAQ
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo® (lenacapavir), the company’s twice-yearly injectable HIV-1 capsid inhibitor that provides adults and adolescents (≥35kg) at risk of HIV-1 acquisition with a new, highly effective option fo...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
30.10.2025
GILD
LISTED
NASDAQ
Gilead Sciences Announces Third Quarter 2025 Financial Results
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2025 results of operations.
“We continue to deliver on Gilead's robust portfolio with a strong start for Yeztugo, rapidly growing uptake of Biktarvy, Descovy and Livdelzi, and positive data for Trodelvy in 1L metastatic triple negative breast cancer,” said Daniel O’Day, Gilea...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2025
GILD
LISTED
NASDAQ
Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with liver disease at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), November 7-11 in Washington, D.C. Key findings from more than 35 accepted abstracts across...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
GILD
LISTED
NASDAQ
LYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS
News Preview
–
LYVDELZI is the Only Medicine to Demonstrate Statistically Significant and Durable Improvements in Both Pruritus and Markers of Cholestasis Related to the Risk of Disease Progression in a Phase 3 Trial
–...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
GILD
LISTED
NASDAQ
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead’s leadership in a...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
GILD
LISTED
NASDAQ
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Trodelvy® (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-neg...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
GILD
LISTED
NASDAQ
Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) to be held in Paris, France from October 15-18. As the leader in HIV innovation, Gilead will provide an update on its strategic initiatives, key collaborations, and share new scientific data from its HIV research and developm...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
GILD
LISTED
NASDAQ
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how cancer is treated with new data at the European Society for Medical Oncology (ESMO) 2025 Congress October 17 – 21.
Potentially Practice-Changing Results for First-Line Metastatic TNBC Treatment
A late-breaking presentat...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2025
GILD
LISTED
NASDAQ
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October 30, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2025 financial results and provide a business upda...
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2025
GILD
LISTED
NASDAQ
Gilead Foundation Grants $6.5 Million in Commitment to STEM Education
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has committed more than $6.5 million in grant funding toward strengthening science, technology, engineering and math (STEM) education pathways in the San Francisco Bay Area and beyond. The funding, distributed through the Gilead Foundation, will build on the company’s ongoing work to cul...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2025
GILD
LISTED
NASDAQ
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). This is a key component of Gilead’s...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2025
GILD
LISTED
NASDAQ
Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of Choose U™, a new campaign that spotlights the multifaceted experiences of people living with HIV globally. The timing of the campaign launch coincides with the convening of the 2025 United States Conference on HIV/AIDS (USCHA) taking place September 4-7 in Washington DC, which will...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2025
GILD
LISTED
NASDAQ
Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy
News Preview
Gilead Sciences (Nasdaq: GILD) today celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City headquarters. This milestone marks continued momentum in Gilead’s multi-year strategy to drive growth and scientific leadership across virology, oncology,...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2025
GILD
LISTED
NASDAQ
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acq...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2025
GILD
LISTED
NASDAQ
Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
News Preview
Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2025082...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2025
GILD
LISTED
NASDAQ
Gilead Sciences to Present at Upcoming Investor Conferences
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Cantor Global Healthcare Conference on Wednesday, September 3 at 11:30 AM Eastern Time
Wells Fargo Healthcare Conference on Thursday, September 4 at 11:00 AM Eastern Time
Morgan Stanley Annual Global Healthcar...
Themefolio
Profiler
Peergroup
© BusinessWire
25.07.2025
GILD
LISTED
NASDAQ
Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion under accelerated review recommending lenacapavir—the company’s injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexu...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
GILD
LISTED
NASDAQ
Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2025 financial results and guidance will be released on Thursday, August 7, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2025 financial results and provide a business upda...
Themefolio
Profiler
Peergroup
© BusinessWire
15.07.2025
GILD
LISTED
NASDAQ
GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or “the Company”) (NASDAQ: GILD) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to...
Themefolio
Profiler
Peergroup
© BusinessWire
14.07.2025
GILD
LISTED
NASDAQ
Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 PURPOSE trial data at IAS 2025 showing that twice-yearly lenacapavir (Yeztugo®) was effective and well tolerated among a broad range of populations who need or want pre-exposure prophylaxis (PrEP) for HIV prevention, including pr...
Themefolio
Profiler
Peergroup
© BusinessWire
09.07.2025
GILD
LISTED
NASDAQ
Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to supply lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). Through the agreement, Gilead will supply enoug...
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
GILD
LISTED
NASDAQ
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
News Preview
Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potent...
Themefolio
Profiler
Peergroup
© BusinessWire
18.06.2025
GILD
LISTED
NASDAQ
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice...
Themefolio
Profiler
Peergroup
© BusinessWire
01.06.2025
GILD
LISTED
NASDAQ
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
News Preview
Kite, a Gilead Company (Nasdaq: GILD), today announced real-world data evaluating the safety and effectiveness of Yescarta® (axicabtagene ciloleucel) for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) assigned to treatment in an outpatient setting (no planned hospital stay) versus those assigned to an inpatient setting in a hos...
Themefolio
Profiler
Peergroup
© BusinessWire
31.05.2025
GILD
LISTED
NASDAQ
Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk of disease progression or death by 35% (HR: 0.65) versus standard of care Keytruda plus chemotherapy in first-line treatment for patients with PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC)....
Themefolio
Profiler
Peergroup
© BusinessWire
23.05.2025
GILD
LISTED
NASDAQ
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy® (sacituzumab govitecan-hziy). The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy in patients...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
GILD
LISTED
NASDAQ
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) will present more than 20 abstracts across both Gilead and Kite at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting May 30 – June 3 and the 2025 European Hematology Association (EHA) Annual Congress June 12 – 15. The studies span breast cancer and other solid tumors (glioblastoma, e...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
GILD
LISTED
NASDAQ
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
News Preview
Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV) treated with the first-in-class entry inhibitor bulevirtide at either a 2 mg or 10 mg dose maintained virologic suppression for almost two years after st...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
GILD
LISTED
NASDAQ
Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment of primary biliary cholangitis (PBC) and also provides sustained biochemical response in adults with PBC regardless o...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
GILD
LISTED
NASDAQ
Gilead Sciences to Present at Upcoming Investor Conferences
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
BofA Securities Health Care Conference on Tuesday, May 13 at 11:20 AM Pacific Time
RBC Capital Markets Global Healthcare Conference on Wednesday, May 21 at 11:30 AM Eastern Time
Bernstein Annual Strategic Decisio...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
GILD
LISTED
NASDAQ
Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
News Preview
Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, May 7-10, 2025, Amsterdam, furthering Gilead’s commitment to transform the lives of people living with liver disease.
New data to be presented at EASL will include a subgroup analysis from ASSURE...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
GILD
LISTED
NASDAQ
Gilead Sciences Announces First Quarter 2025 Financial Results
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations.
“Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Our base business grew 4% year-over-year, pri...
Themefolio
Profiler
Peergroup
© BusinessWire
21.04.2025
GILD
LISTED
NASDAQ
Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) significantly improved progression-free survival (PFS) compared to Keytruda and chemotherapy in patients with inoperable (unresectable)...
Themefolio
Profiler
Peergroup
© BusinessWire
10.04.2025
GILD
LISTED
NASDAQ
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s first quarter 2025 financial results and provide a business update...
Themefolio
Profiler
Peergroup
© BusinessWire
12.03.2025
GILD
LISTED
NASDAQ
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). The new findings reflect a transformative portfolio and a rapidly advancing forward-looking...
Themefolio
Profiler
Peergroup
© BusinessWire
11.03.2025
GILD
LISTED
NASDAQ
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). The data were presented during an oral abstract sessi...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
GILD
LISTED
NASDAQ
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s Marketing Authorization Application (MAA) and EU-Medicines for all (EU-M4all) application for lenacapavir—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
GILD
LISTED
NASDAQ
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to to...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
GILD
LISTED
NASDAQ
Gilead Sciences to Present at Upcoming Investor Conferences
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
TD Cowen Annual Health Care Conference on Tuesday, March 4 at 11:10 AM Eastern Time
Leerink Partners Global Healthcare Conference on Tuesday, March 11 at 10:40 AM Eastern Time
The live webcasts can be accessed at t...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
GILD
LISTED
NASDAQ
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP).
The FDA will review the applications under priority...
Themefolio
Profiler
Peergroup
© BusinessWire
11.02.2025
GILD
LISTED
NASDAQ
Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.6% in the company’s quarterly cash dividend, beginning in the first quarter of 2025. The increase will result in a quarterly dividend of $0.79 per share of common stock. The dividend is payable on March 28, 2025, to stockholders...
Themefolio
Profiler
Peergroup
© BusinessWire
11.02.2025
GILD
LISTED
NASDAQ
Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.
“Gilead delivered another exceptionally strong full year and fourth quarter, with growth in our base business product sales of 8% for 2024 and 13% year-over-year for the fourth quarter,” said Daniel O’Day, Gilead’s Chairman a...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2025
GILD
LISTED
NASDAQ
Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released on Tuesday, February 11, 2025, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2024 financial...
Themefolio
Profiler
Peergroup
© BusinessWire
11.01.2025
GILD
LISTED
NASDAQ
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential treatment of patients with inflammatory diseases.
This press release features mult...
Themefolio
Profiler
Peergroup
© BusinessWire
20.12.2024
GILD
LISTED
NASDAQ
Gilead Sciences to Present at Upcoming Investor Conference
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:
J.P. Morgan Healthcare Conference on Monday, January 13, 2025 beginning at 11:15 a.m. Pacific Time
The live webcast can be accessed at investors.gilead.com and the replay will be available for at least 30 days follo...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
GILD
LISTED
NASDAQ
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy....
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
GILD
LISTED
NASDAQ
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241217141411...
Themefolio
Profiler
Peergroup
© BusinessWire
13.12.2024
GILD
LISTED
NASDAQ
Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate respons...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
GILD
LISTED
NASDAQ
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead’s senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD.
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
